



**Supplemental Information:**  
**SUPPLEMENTAL FIGURES**

**Suppl. Fig. 1:**




**Suppl. Fig. 1: Diabetes increases splenic and blood myeloid cell content: Related to Figure 2.** C57BL/6 mice fed on chow diet were injected with stz for 5 days to induce diabetes. One of three independent experiments is shown. **A)** Representative flow cytometry plots and quantification of different myeloid cells using flow cytometry. **B)** Representative confocal images showing splenic CD11b<sup>+</sup> cells. The bar graph represents quantification of splenic myeloid cells in C57BL/6 mice 8 weeks after stz treatment. (Scale bar = 20 μm). **C)** Representative flow cytometry plots and quantification of different myeloid cells in the blood. **D)** Frequency of different myeloid cells in the spleens of non-diabetic and diabetic mice. **E)** The flow cytometric plots show gating strategies for B and T lymphocytes. The bar graphs depict frequencies of the lymphocytes in the blood in diabetic and non-diabetic C57BL/6 mice. Data from one of three independent experiments are shown. **F)** BrdU<sup>+</sup> GMP in the spleen after 2 weeks of BrdU injection in C57BL/6 mice. n=5-6 mice/ time point/ group (A-C) and n=5 mice/ group (D-F). Mean ± s.e.m. \* P < 0.05, \*\* P < 0.01.

Suppl. Fig. 2:




**Suppl. Fig. 2: Splenic nerves and leukocytes express TH: Related to Figure 4.** A) Confocal images showing TH staining in PGP9.5<sup>+</sup> nerves and CD45<sup>+</sup> leukocytes in the spleen of diabetic C57BL/6 mice. (Scale bar = 50  $\mu$ m). B) Representative flow cytometric gating strategy for T cells, neutrophils, macrophages and dendritic cells in human spleen. n=4-5 samples/ group.

**Suppl. Fig. 3:**



**Suppl. Fig. 3: Diabetes increases TH-expressing leukocytes in the spleens of *Th-cre-ROSA-tdTomato* mice: Related to Figure 4.** Flow cytometric plots (A) and confocal images (B) show tdTomato<sup>+</sup> leukocytes. (Scale bar = 50  $\mu$ m). C) Flow cytometric plots showing tdTomato expression in monocytes. D) The bar graph shows TH expression in THP-1 monocytes and macrophages derived from this cell line using quantitative RT-PCR. Enumeration of splenic tdTomato<sup>+</sup> leukocyte populations by flow cytometry (E) and confocal microscopy (F) n=7 per group. The experiments were independently repeated. n=5-6 mice (A,B,C,E&F) and n=8 samples/group (D). Mean  $\pm$  s.e.m. \* P < 0.05, \*\* P < 0.01.


**Suppl. Fig. 4:**



**Suppl. Fig. 4: Splenic sympathectomy does not affect the frequency, number and proliferation of GMP in the BM: Related to Figure 6.** **A)** Quantification and **(B)** cell cycle analysis of GMP in the BM. Myeloid cell content in the blood **(C)** and femur **(D)** after surgical splenic sympathectomy. Distances between TH<sup>+</sup> **(E)** and TH<sup>-</sup> **(F)** leukocytes and splenic nerves were quantified by confocal microscopy. **G)** Schematic diagram showing the experimental design. Flow cytometric quantification of myeloid cells and monocytes in the spleen **(H)** and blood **(I)** after TH<sup>+</sup> leukocyte depletion with DT in in wild type mice reconstituted with BM from *Th-cre-ROSA-iDTR*. Splenic myeloid cell number **(J)** and GMP proliferation **(K)** were determined by flow cytometry in *Th-cre-ROSA-iDTR* mice reconstituted with BM from wild type mice after DT-mediated depletion of splenic neurons. All the experiments with the


exception of splenic neuron depletion were performed at least twice. n=8-9 mice/ group (A-D), n=8/ group (E&F), n=6-7 mice/ group (H&I) and n=4 mice/ group (J&K). Mean  $\pm$  s.e.m. \* P < 0.05.

Suppl. Fig. 5:



**Suppl. Fig. 5: Accelerated atherosclerosis in diabetic mice: Related to Figure 7.** *Apoe*<sup>-/-</sup> mice were fed on a high fat diet for 2 months and injected with stz for 5 days to induce type-1 diabetes. Control group received Na citrate buffer. **A**) Shows representative flow cytometric gating strategy for myeloid cells, neutrophils, monocytes and macrophages in the aorta at 8 weeks after stz injection. The bar graphs depict quantification of the myeloid cells. **B**) Immunological staining showing CD11b<sup>+</sup> area in aortic roots. (Scale bar = 150 μm). **C**) Histopathological images of aortic roots stained with Masson's trichrome. The arrows point at the fibrous caps above the necrotic cores. (Scale bar = 50 μm). The bar graphs show quantification of plaque area and fibrous cap thickness. The data are pooled from two independent experiments. n=6 mice/group. Mean ± s.e.m. \*\* *P* < 0.01.


Suppl. Fig. 6:



Suppl. Fig. 6: Diabetes increases myeloid cell content in the spleen and blood of *Apoe*<sup>-/-</sup> mice: Related to Figure 7. **A**) Shows representative flow cytometric gating strategy and quantitation of splenic myeloid cells, neutrophils, monocytes and Ly-6C<sup>hi</sup> monocytes. **B**) Quantification of myeloid cells in the blood. **C**) Enumeration of splenic GMP by flow cytometry. **D**) Flow cytometric enumeration of myeloid cells and inflammatory monocytes in the aortas of *Apoe*<sup>-/-</sup> mice 4 weeks after splenectomy. **E**) Quantification of atherosclerotic plaque area and fibrous cap thickness in aortic roots using Masson's trichrome staining. n=5 mice/ group. Mean  $\pm$  s.e.m. \* P < 0.05.



Suppl. Fig. 7:



**Suppl. Fig. 7: Splenic myelopoiesis triggered by sympathetic activation accelerates atherosclerosis in diabetic *ApoE*<sup>-/-</sup> mice: Related to Figure 7.** **A)** Flow cytometric plots showing splenic myeloid cells after 6-OHDA treatment. **B)** Confocal images show CD11b<sup>+</sup> cells in the spleen. **C)** Representative flow cytometric plots for macrophages and monocytes in the aortas of *ApoE*<sup>-/-</sup> mice after 6-OHDA treatment. (Scale bar = 5 μm). **D)** Bright field microscopic images and quantification of CD11b<sup>+</sup> cells in the aortic root. (Scale bar = 150 μm). Histopathological images of aortic roots stained with Masson's trichrome show plaque area and fibrous cap thickness in aortic roots after 6-OHDA treatment (**E**) (Scale bar = 50 μm) and splenic sympathectomy (**F**) (Scale bar = 50 μm). **G)** Enumeration of donor-derived myeloid cells in the blood and spleen of recipient non-diabetic (control) and diabetic *ApoE*<sup>-/-</sup> mice three weeks after spleen transplantation. n=4-6 per group. **H)** Flow cytometric plots showing frequency of aortic macrophages in diabetic *ApoE*<sup>-/-</sup> mice injected with either PBS or ACE inhibitor. n=5 per group. **I)** Masson's trichrome staining to measure plaque area and fibrous cap thickness in diabetic *ApoE*<sup>-/-</sup> mice injected with either PBS or NE. n=5 per group. (Scale bar = 150 μm). **J)** Catecholamine secretion by macrophages in culture in presence or absence of reserpine. n=6 per group. **K)** Enumeration of catecholamine<sup>+</sup> splenic nerve termini and leukocytes after reserpine treatment in diabetic *ApoE*<sup>-/-</sup> mice. The yellow and white arrows point at catecholamine<sup>+</sup> splenic nerves and leukocytes, respectively. n=5 per group. (Scale bar = 3 μm). **L)** The numbers of myeloid subsets in the femur were quantified in non-diabetic and diabetic mice using flow cytometry. n=5 per group. Data from one of three independent experiments are shown. **M)** Enumeration of tdTomato<sup>+</sup> leukocytes in the BM of *Th-cre-ROSA-tdTomato* mice. n=7 per group. **N)** The numbers of myeloid progenitors and GMP in the BM were determined by flow cytometry in diabetic mice expressing iDTR in hematopoietic cells after DT injection. n=6-7 per group. **O)** Myeloid cell number and GMP proliferation in the femur were determined by flow cytometry in diabetic mice after PBS or β<sub>2</sub> blocker treatment. n=9-10 per group. All of these experiments were repeated at least twice. n=6/ group (A-D), n=7-9/ group (E&F), n=4-6/ group (G-L), n=6-7/ group (M&N) and n=9-10 mice/ group (O). Mean ± s.e.m. \* P < 0.05, \*\* P < 0.01.